Clinical Trials Browser

Phase 1/2 × devimistat × Sarcoma × Clear all

NCT04593758 2023-05-24

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Phase 1/2 Completed

Sarcoma, Clear Cell